Eikon Therapeutics clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   TeLuRide-008 · EIK1001 in Combination With Pembrolizumab and…TeLuRide-008 · EIK1001 in Combination With Pembrolizumab and Chemotherapy · Stage 4 Non-Small Cell Lung Cancer

   Trial sites expanded: 28 → 32 locations

   And 1 more change in the last 30 days

   Eikon Therapeutics·Phase 2/3· NCT07365319· Registry history of NCT07365319 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

2. Minor

   EIK1001 in Combo With Pembro Versus Placebo and Pembro as…EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy · Advanced Melanoma

   Trial sites expanded: 107 → 127 locations

   Eikon Therapeutics·Phase 2/3· NCT06697301· Registry history of NCT06697301 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

3. Minor

   EIK1005-002 · Research Study Evaluating EIK1005, a Werner…EIK1005-002 · Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab · Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   Trial sites expanded: 10 → 35 locations

   Eikon Therapeutics·Phase 1/2· NCT07262619· Registry history of NCT07262619 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.